Analyzing...
Loading company...
No significant concerns identified
Nothing flagged for monitoring
“Operates in Pharmaceuticals — Formulations & API.”
₹6,409 Cr revenue.
COGS 54.6%, employees 9.2%.
| KPI | Company | Sector Median |
|---|---|---|
| ROE | 38.0%▲ | 10.5% |
| ROCE | 48.0%▲ | 13.8% |
| Net Margin | 21.4%▲ | 8.7% |
| EBITDA Margin | 29.9%▲ | 16.0% |
| Debt To Equity | 0.00x▼ | 0.21x |
Revenue segment breakdown not available.
| (₹ Cr) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| Revenue | ₹6,409 Cr +9.6% | ₹5,849 Cr +9.4% | ₹5,349 Cr +8.7% | ₹4,919 Cr +14.1% | ₹4,310 Cr +5.3% | ₹4,093 Cr +11.3% | ₹3,679 Cr |
| Other Income | ₹276 Cr +11.0% | ₹248 Cr +61.1% | ₹154 Cr +99.7% | ₹77 Cr -4.6% | ₹81 Cr -29.3% | ₹114 Cr +1.0% | ₹113 Cr |
| Total Income | ₹6,685 Cr +9.6% | ₹6,097 Cr +10.8% | ₹5,503 Cr +10.1% | ₹4,996 Cr +13.8% | ₹4,391 Cr +4.4% | ₹4,208 Cr +11.0% | ₹3,792 Cr |
| COGS | ₹3,497 Cr +8.6% | ₹3,221 Cr +8.3% | ₹2,975 Cr +12.0% | ₹2,657 Cr +11.1% | ₹2,391 Cr +3.3% | ₹2,316 Cr +10.9% | ₹2,089 Cr |
| ₹4,798 Cr +7.1% | ₹4,479 Cr +5.9% | ₹4,229 Cr +8.0% | ₹3,917 Cr +13.0% | ₹3,465 Cr +1.8% | ₹3,405 Cr +10.1% | ₹3,093 Cr | |
| Profit Before Tax | ₹1,887 Cr +16.6% | ₹1,618 Cr +27.0% | ₹1,274 Cr +18.0% | ₹1,080 Cr +16.6% | ₹926 Cr +15.4% | ₹803 Cr +14.9% | ₹699 Cr |
| ₹473 Cr +13.4% | ₹417 Cr +28.4% | ₹324 Cr +15.4% | ₹281 Cr +19.5% | ₹235 Cr +12.2% | ₹210 Cr -15.6% | ₹249 Cr | |
| Net Profit | ₹1,414 Cr +17.8% | ₹1,201 Cr +26.5% | ₹949 Cr +18.9% | ₹799 Cr +15.6% | ₹691 Cr +16.5% | ₹593 Cr +31.7% | ₹450 Cr |
| Other Comprehensive Income | (₹5 Cr) ↓ Decline | ₹0.02 Cr -99.4% | ₹4 Cr +24.0% | ₹3 Cr +133.6% | ₹1 Cr ↑ Recovery | (₹5 Cr) -136.8% | (₹2 Cr) |
| EPS | ₹665.64 | ₹565.30 | ₹446.80 | ₹375.87 | ₹325.04 | ₹279.04 | ₹211.93 |
| Diluted Shares | ₹2 Cr | ₹2 Cr | ₹2 Cr | ₹2 Cr | ₹2 Cr | ₹2 Cr | ₹2 Cr |
No related party data available for this company.
This section will be populated when data becomes available.
No earnings call transcripts available.
No regulatory filings available.
Disclaimer · The Stock Filter is an information platform, not a SEBI-registered investment adviser. All data, scores, and narratives are generated from public filings and AI analysis — they do not constitute investment advice, recommendations, or endorsements. Always consult a qualified financial adviser before making investment decisions. Past performance does not guarantee future results.